Physician profile
Dustin Markle
NPI 1245529437
$1,672.26
in general payments reported to CMS, 2019-2025
24 companies · $229 in 2025
The $229 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $220 · 2020: $76.01 · 2021: $105 · 2022: $401 · 2023: $410 · 2024: $233 · 2025: $229.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $871.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $871.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $593.14 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Pfizer INC. | $195.23 | 2019-2025 | |
| Abbvie INC. | $176.19 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $76.30 | 2022-2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $73.42 | 2022-2024 | Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $72.22 | 2021-2024 | Jardiance, Synjardy, Ofev |
| Takeda Pharmaceuticals U.S.A., INC. | $50.74 | 2021-2022 | |
| Amgen INC. | $48.98 | 2019-2023 | Prolia, Evenity |
| Novo Nordisk INC | $41.63 | 2019-2025 | Wegovy |
| Novartis Pharmaceuticals Corporation | $36.06 | 2024 | |
| Dexcom, INC. | $34.72 | 2025 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $31.97 | 2019 | |
| Boston Scientific Corporation | $29.47 | 2025 | Accolade Sr |
| Xeris Pharmaceuticals, INC. | $29.10 | 2022 | |
| Phathom Pharmaceuticals, INC. | $27.76 | 2024 | Voquezna |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $21.97 | 2023 | Rexulti |
| Insulet Corporation | $21.45 | 2019 | |
| Abbott Laboratories | $19.04 | 2022 | |
| Amarin Pharma, INC. | $18.32 | 2019 | |
| Averitas Pharma INC. | $18.32 | 2023 | Qutenza |
| Ironwood Pharmaceuticals, INC | $14.73 | 2023 | Linzess |
| Mallinckrodt Enterprises LLC | $14.21 | 2019 | |
| Astellas Pharma US INC | $14.01 | 2023 | Veozah |
| Glaxosmithkline, LLC. | $13.28 | 2023 | Shingrix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dustin Markle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.